Glucose-dependent Insulinotropic Polypeptide (GIP) Profile

Gastric Inhibitory Polypeptide (GIP) is an incretin hormone that plays a crucial role in glucose homeostasis by stimulating insulin secretion from pancreatic β cells, enhancing fat deposition, and influencing appetite regulation and bone metabolism. GIP demonstrates distinct physiological effects compared to another incretin, GLP-1, particularly in the context of type 2 diabetes.

GIP is an incretin hormone produced in the gut that enhances insulin secretion in response to glucose. It has diverse effects beyond insulin regulation, including roles in fat deposition, bone formation, and potential impacts on appetite and memory.

LL-37 is a human cathelicidin antimicrobial peptide involved in immune responses, showing properties of both antimicrobial activity and cytotoxicity towards host cells. It has been implicated in various physiological and pathophysiological processes, including immune activation and inflammation.

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most effective weight loss medications available. It works by mimicking a natural hormone that regulates appetite and blood sugar, helping people feel full faster and longer.